Oncology News | pharmaphorum

News

Lilly brings second oral SERD to market for breast cancer

Lilly's Inluriyo is the second oral SERD to reach the US market for ESR1-mutated breast cancer, setting up a market tussle with Menarini's Orserdu.

News

BMS eyes filings for myeloma 'celmod' iberdomide

Bristol Myers Squibb has said it hopes to be ready soon to file for approval of its multiple myeloma drug iberdomide after a positive phase 3 trial.

News

Roche's oral SERD comes good in 2nd-line breast cancer trial

Roche has staked a claim to use its oral SERD giredestrant as a second-line therapy for breast cancer, regardless of a patient's ESR1 mutation status.

News

FDA clears subcutaneous Keytruda in a boost to MSD

MSD's Keytruda will soon be available as a subcutaneous injection, improving convenience for patients and defending it from a looming patent loss.

News

Imfinzi becomes first NHS drug for aggressive lung cancer

AstraZeneca's PD-L1 inhibitor Imfinzi is the first drug therapy to be recommended for routine NHS use in limited-stage small cell lung cancer.

News

J&J claims FDA okay for bladder cancer drug TAR-200

Johnson & Johnson has brought its bladder cancer drug TAR-200 to the US market, a year after its prospects were dented by a negative phase 3 readout.

Lilly brings second oral SERD to market for breast cancer

BMS eyes filings for myeloma 'celmod' iberdomide

Roche's oral SERD comes good in 2nd-line breast cancer trial

FDA clears subcutaneous Keytruda in a boost to MSD

Imfinzi becomes first NHS drug for aggressive lung cancer

J&J claims FDA okay for bladder cancer drug TAR-200

Zuckerberg, Chan's Biohub launches protein 'world model'

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks